Both neurogranin and SNAP-25 were markedly decreased in the CSF of AME patients at presentation. Lower SNAP-25 in prospectively followed patients and higher neurogranin at presentation is associated with greater disease severity. Here, NRGN is linked to apparent mineralocorticoid excess.